Clinical Trial Update: Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating zimberelimab and quemliclustat with chemotherapy for borderline resectable or locally advanced pancreatic ductal adenocarcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Resectable Pancreatic Cancer
• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Quemliclustat (Quemliclustat)
• Zimberelimab (zimberelimab)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING